Effect of liraglutide on serum androgen levels and sexual function in obese women
PDF (Español (España))
xhtml (Español (España))


Sexual Health
Quality of Life

How to Cite

De la Hoz, F. E. (2022). Effect of liraglutide on serum androgen levels and sexual function in obese women. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 8(3). https://doi.org/10.53853/encr.8.3.685


Objective. To analyze the variations in serum androgen levels and sexual function in women with obesity, after treatment with liraglutide and to establish their impact on quality of life.

Methods. Prospective, quasi-experimental pilot study, developed in 15 women with obesity; treated with liraglutide, between January and October 2020; in a private level III clinic in Armenia (Colombia). The serum levels of Total Testosterone (Tt), Free Testosterone (Tl), Androstenedione (A) and SHBG (Sex hormone binding globulin) were quantified. The Female Sexual Function Index (IFSF) instruments and the SF-36 Health Questionnaire were used. Four follow-ups were carried out (at the beginning, at four, eight and twelve weeks later). Descriptive statistics were applied.

Results. The average age was 37.41 ± 5.28 years (lower 27 and higher 45). The mean serum androgen levels at baseline were: Tt (0.39 ± 0.12 ng / ml), Tl (5.49 ± 1.37 pg / ml), A (2.58 ± 1.13 ng / ml) and SHBG (26.94 ± 13.74 ng / ml), and at the end: Tt (0.81 ± 0.15 ng / ml), Tl (12.57 ± 3.89 pg / ml), A (3.87 ± 1.28 ng / ml) and SHBG (49.62 ± 15.57 ng / ml), (p <0.05). The mean score of the SF-36 Health Questionnaire at the beginning was 63.91 ± 15.19 and at the end it was 79.63 ± 15.13 (p <0.05). The IFSF at the beginning was 23.47 ± 6.97 and at the end of 27.97 ± 6.45 (p <0.05). A clear improvement was observed in both sexual function and quality of life.

Conclusions. Liraglutide produced a significant increase in serum levels of Tt, Tl, A and SHBG; in addition to improving the sexual function and quality of life of the participating women. Liraglutide could become a promising drug for the treatment of obesity, achieving positive effects on sexual function and quality of life in women.

PDF (Español (España))
xhtml (Español (España))


Rössner S. Obesity: the disease of the twenty-first century. Int J Obes Relat Metab Disord. 2002; 26 Suppl 4:S2-S4. doi: 10.1038/sj.ijo.0802209

Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983; 67(5):968-977. doi: 10.1161/01.cir.67.5.968

Bhurosy T, Jeewon R. Overweight and obesity epidemic in developing countries: a problem with diet, physical activity, or socioeconomic status? Scientific World Journal. 2014; 2014:964236. doi: 10.1155/2014/964236

World Health Organisation. Obesity and overweight. Geneva: WHO; 2020. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.

Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju ShN, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet. 2016; 388(10046):776-86. doi: 10.1016/S0140-6736(16)30175-1

Upadhyay J, Farr O, Perakakis N, Ghaly W, Mantzoros C. Obesity as a Disease. Med Clin North Am. 2018; 102(1):13-33. doi: 10.1016/j.mcna.2017.08.004

Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body Fatness and Cancer--Viewpoint of the IARC Working Group. N Engl J Med. 2016; 375(8):794-798. doi: 10.1056/NEJMsr1606602

Pérez Pérez A, Ybarra Muñoz J, Blay Cortés V, de Pablos Velasco P. Obesity and cardiovascular disease. Public Health Nutr. 2007; 10(10A):1156-1163. doi: 10.1017/S1368980007000651

Stegenga H, Haines A, Jones K, Wilding J; Guideline Development Group. Identification, assessment, and management of overweight and obesity: summary of updated NICE guidance. BMJ. 2014; 349:g6608. Published 2014. doi: 10.1136/bmj.g6608

Brauer P, Gorber SC, Shaw E, et al. Recommendations for prevention of weight gain and use of behavioural and pharmacologic interventions to manage overweight and obesity in adults in primary care. CMAJ. 2015; 187(3):184-95. doi: 10.1503/cmaj.140887

Kinch MS, Umlauf S, Plummer M. An analysis of FDA-approved drugs for metabolic diseases. Drug Discov Today. 2015; 20(6):648-651. doi: 10.1016/j.drudis.2015.02.002

Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014; 311(1):74-86. doi: 10.1001/jama.2013.281361

Halpern B, Halpern A. Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications. Expert Opin Drug Saf. 2015; 14(2):305-315. doi: 10.1517/14740338.2015.994502

Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007; 87(4):1409-1439. doi: 10.1152/physrev.00034.2006

Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019; 10:155. Published 2019. doi: 10.3389/fendo.2019.00155

van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond). 2014; 38(6):784-793. doi: 10.1038/ijo.2013.162

Nuffer WA, Trujillo JM. Liraglutide: A New Option for the Treatment of Obesity. Pharmacotherapy. 2015; 35(10):926-934. doi: 10.1002/phar.1639

Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study [published correction appears in Lancet. 2010 Mar 20;375(9719):984]. Lancet. 2009; 374(9701):1606-16. doi: 10.1016/S0140-6736(09)61375-1

Saxenda (liraglutide 3.0 mg) prescribing information. Silver Spring, MD: Food and Drug Administration, 2014 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf).

Saxenda 6 mg/ml solution for injection in pre-filled pen prescribing information. London: European Medicines Agency, 2015 (https://www.ema.europa.eu/en/documents/product-information/saxenda-epar-product-information_en.pdf)

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375(4):311-22. doi: 10.1056/NEJMoa1603827

le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial [published correction appears in Lancet. 2017 Apr 8;389(10077):1398]. Lancet. 2017; 389(10077):1399-409. doi: 10.1016/S0140-6736(17)30069-7

Espitia De La Hoz FJ. Prevalence and characterisation of sexual dysfunctions in women, in 12 Colombian cities, 2009-2016. Rev Colomb Obstet Ginecol 2018; 69(1):9-21. doi: 10.18597/rcog.3035

Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D'Agostino R Jr. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000; 26(2):191-208. doi: 10.1080/009262300278597

Ware JE Jr. SF-36 health survey update. Spine (Phila Pa 1976). 2000; 25(24):3130-3139. doi: 10.1097/00007632-200012150-00008

Alonso J, Prieto L, Antó JM. La versión española del SF-36 Health Survey (Cuestionario de Salud SF-36): un instrumento para la medida de los resultados clínicos [The Spanish version of the SF-36 Health Survey (the SF-36 health questionnaire): an instrument for measuring clinical results]. Med Clin (Barc). 1995; 104(20):771-776.

Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30(6):473-483.

World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310(20):2191-4. doi: 10.1001/jama.2013.281053

Ministerio de Salud. República de Colombia. Resolución 8430 de 1993 – octubre 4. Por la cual se establecen las normas científicas, técnicas y administrativas para la investigación en salud. (Internet) Ministerio de Salud de Colombia. (Actualizado 4 de octubre de 2018. Consultado octubre 4 de 2021). Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/RESOLUCION-8430-DE-1993.PDF

Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide [published correction appears in Int J Obes (Lond). 2012 Jun;36(6):890] [published correction appears in Int J Obes (Lond). 2013 Feb;37(2):322]. Int J Obes (Lond). 2012; 36(6):843-54. doi: 10.1038/ijo.2011.158

Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study [published correction appears in Int J Obes (Lond). 2013 Nov;37(11):1514] [published correction appears in Int J Obes (Lond). 2015 Jan;39(1):187]. Int J Obes (Lond). 2013; 37(11):1443-51. doi: 10.1038/ijo.2013.120

Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015; 373(1):11-22. doi: 10.1056/NEJMoa1411892

Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab. 2009; 11 Suppl 3:26-34. doi: 10.1111/j.1463-1326.2009.01075.x

Lin CH, Shao L, Zhang YM, et al. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. Expert Opin Pharmacother. 2020; 21(3):275-85. doi: 10.1080/14656566.2019.1695779

Garvey WT, Birkenfeld AL, Dicker D, et al. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. Diabetes Care. 2020; 43(5):1085-1093. doi: 10.2337/dc19-1745

Tak YJ, Lee SY. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?. Curr Obes Rep. 2021; 10(1):14-30. doi: 10.1007/s13679-020-00422-w

Alba M, Yee J, Frustaci ME, Samtani MN, Fleck P. Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study. Clin Obes. 2021; 11(2):e12432. doi: 10.1111/cob.12432

Espitia De La Hoz FJ. Disfunciones sexuales en mujeres con obesidad en el Quindío, Colombia. 2016-2019. Estudio de prevalencia. Universitas Medica. 2021; 62(3):1-9. Doi: 10.11144/Javeriana.umed62-3.dsmo

Moon S, Lee J, Chung HS, et al. Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials. Endocrinol Metab (Seoul). 2021; 36(3):647-660. doi: 10.3803/EnM.2020.934

Simpson ER, Davis SR. Minireview: aromatase and the regulation of estrogen biosynthesis--some new perspectives. Endocrinology. 2001 Nov;142(11):4589-94. doi: 10.1210/endo.142.11.8547

Montorsi F, Oettel M. Testosterone and sleep-related erections: an overview*. J Sex Med. 2005; 2(6):771-784. doi: 10.1111/j.1743-6109.2005.00095.x

Espitia De La Hoz FJ. Terapia de reemplazo hormonal combinada con testosterona para el tratamiento del trastorno del deseo sexual hipoactivo en mujeres en climaterio. Arch Med (Manizales) 2020; 20(1):71-85. doi: 10.30554/archmed.20.1.3388.2020

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2021 Revista Endocrino


Download data is not yet available.